Market Overview:

Orodispersible tablets are oral solid dosage forms that disintegrates or dissolves rapidly within a matter of seconds when placed on tongue without need of water. These tablets offer significant advantages such as accessibility to pediatric and geriatric patients who face difficulty in swallowing conventional tablets and capsules. The technology used in orodispersible tablets allows them to rapidly disintegrate and release the drug upon contact with saliva, permitting transmucosal absorption of drugs in the oral cavity as well as pre-gastric absorption of drugs from the stomach, improving bioavailability of drugs.

The global Orodispersible Tablets Market is estimated to be valued at US$ 4.9 Bn in 2023 and is expected to exhibit a CAGR of 8.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/orodispersible-tablets-market-5745

Market key trends:

Growing geriatric population prone to dysphagia and increasing patient non-adherence to medication due to difficult dosages are some of the major factors propelling the growth of global orodispersible tablets market. According to Population Reference Bureau, number of Americans aged 65 years or above is projected to reach ~95 million by 2060 from ~56 million in 2018. Moreover, as per estimates by United Nations, number of people aged 60 years or above will grow to ~1.4 billion in 2030 from ~900 million in 2015. Another significant trend is emergence of more effective technologies for manufacturing orodispersible tablets using innovative techniques for rapid disintegration, increasing uptake of these tablets for various therapeutic applications.

Porter’s Analysis

Threat of new entrants: The growing market size and demand for orodispersible tablets provide high opportunity for new players, however existing regulatory barriers and intellectual property rights of key innovators pose threat to the new entrants.
Bargaining power of buyers: Growing demand for patient-centric dosage forms that are easy to administer increases the bargaining power of pharmaceutical buyers in the market.
Bargaining power of suppliers: The presence of a large number of API suppliers and excipient manufacturers controls suppliers’ bargaining power in the market.
Threat of new substitutes: Advancements in drug delivery technologies like sublingual films, fast dissolving strips pose potential threat as substitutes.
Competitive rivalry: The global market is highly fragmented with presence of many privately held and publicly traded companies, leading to high competitive rivalry.

Key Takeaways

The global orodispersible tablets market is expected to witness high growth, exhibiting CAGR of 8.1% over the forecast period, due to increasing geriatric population globally and rising preference for patient-centric dosage forms.

Regional analysis: North America dominates the global market and is expected to continue its dominance over the forecast period owing to high healthcare expenditure and presence of major players in the region. However, Asia Pacific region is anticipated to exhibit the fastest growth owing to growing economy, rising disposable income, and increase in healthcare spending in major countries like India and China.

Key players operating in the orodispersible tablets market are Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L. Key players are focusing on new product launches, collaboration and mergers to gain competitive advantage in the market. For instance, in 2022, Alnylam Pharmaceuticals, Inc. launched Oxlumo, an orodispersible tablet for treatment of primary hyperoxaluria.

*Note:

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it